• Return to Headlines

Relatively High EV/EBITDA Ratio Detected in Shares of Amphastar Pharma in the Pharmaceuticals Industry (AMPH, AGN, ZTS, LLY, BMY)

By David Diaz

Below are the three companies in the Pharmaceuticals industry with the highest enterprise value to EBITDA (EV/EBITDA) ratios. EV/EBITDA is an important metric used in valuing comparable companies. It is capital structure neutral and generally the lower the ratio, the more undervalued the company is believed to be.

Amphastar Pharma ranks highest with a an EV/EBITDA ratio of 259.37. Allergan Plc is next with a an EV/EBITDA ratio of 54.33. Zoetis Inc ranks third highest with a an EV/EBITDA ratio of 35.88.

Eli Lilly & Co follows with a an EV/EBITDA ratio of 30.25, and Bristol-Myer Sqb rounds out the top five with a an EV/EBITDA ratio of 23.62.

SmarTrend recommended that subscribers consider buying shares of Eli Lilly & Co on October 31st, 2019 as our technology indicated a new Uptrend was in progress when shares hit $113.34. Since that recommendation, shares of Eli Lilly & Co have risen 24.4%. We continue to monitor Eli Lilly & Co for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: highest ev/ebitda ratio amphastar pharma allergan plc zoetis inc eli lilly & co bristol-myer sqb

Ticker(s): AMPH AGN ZTS LLY BMY